---
figid: PMC12039932__IJN-20-5291-g0005
figtitle: Nanomaterial-based DDSs treat OA by targeting MSCs
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12039932
filename: IJN-20-5291-g0005.jpg
figlink: /pmc/articles/PMC12039932/figure/F4/
number: F4
caption: Nanomaterial-based DDSs treat OA by targeting MSCs. Nanomedicines modified
  with different ligands target MSCs through the corresponding receptors on MSCs to
  release functional drugs. Different nanomedicines regulate MSCs through different
  mechanisms. Firstly, nanomedicines up-regulate the PI3K/AKT/mTOR signaling pathway.
  Secondly, nanomedicines promote glucose transport, thereby releasing more ATP. Thirdly,
  nanomedicines up-regulate HIF-1α. Fourthly, nanomedicines accelerate the release
  of Ca2+ from mitochondria, thereby promoting autophagy. Fifthly, nanomedicines promote
  the transcription of CBFβ -RUNX1. Sixthly, nanomedicines up-regulate Sox9, COL2A1
  and Aggrecan. These nanomedicines eventually stimulate MCSs to differentiate into
  chondrocytes
papertitle: 'Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for
  Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects'
reftext: Hui Kong, et al. Int J Nanomedicine. 2025;20(NA).
year: '2025'
doi: 10.2147/IJN.S518935
journal_title: International Journal of Nanomedicine
journal_nlm_ta: Int J Nanomedicine
publisher_name: Dove Press
keywords: nanomaterial-based drug delivery systems | osteoarthritis | macrophages
  | chondrocytes | synoviocytes | mesenchymal stem cells
automl_pathway: 0.8588933
figid_alias: PMC12039932__F4
figtype: Figure
redirect_from: /figures/PMC12039932__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12039932__IJN-20-5291-g0005.html
  '@type': Dataset
  description: Nanomaterial-based DDSs treat OA by targeting MSCs. Nanomedicines modified
    with different ligands target MSCs through the corresponding receptors on MSCs
    to release functional drugs. Different nanomedicines regulate MSCs through different
    mechanisms. Firstly, nanomedicines up-regulate the PI3K/AKT/mTOR signaling pathway.
    Secondly, nanomedicines promote glucose transport, thereby releasing more ATP.
    Thirdly, nanomedicines up-regulate HIF-1α. Fourthly, nanomedicines accelerate
    the release of Ca2+ from mitochondria, thereby promoting autophagy. Fifthly, nanomedicines
    promote the transcription of CBFβ -RUNX1. Sixthly, nanomedicines up-regulate Sox9,
    COL2A1 and Aggrecan. These nanomedicines eventually stimulate MCSs to differentiate
    into chondrocytes
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - HIF1A
  - AKT1
  - AKT2
  - AKT3
  - COL2A1
  - MTOR
  - ATP8A2
  - Glucose
---
